OBJECTIVE: The cells of the immune system originate from the bone marrow, where many of them also mature. This study was undertaken to examine gene expression in the bone marrow of patients with systemic lupus erythematosus (SLE), in order to better understand the aberrant immune response in this disease. METHODS: Bone marrow mononuclear cells (BMMCs) from 20 SLE patients (11 with active disease and 9 with inactive disease) and peripheral blood mononuclear cells (PBMCs) from 27 patients (16 with active disease and 11 with inactive disease) were studied; BMMCs and PBMCs from 7 healthy individuals and 3 osteoarthritis patients were studied as controls. Samples were analyzed on genome-scale DNA microarrays, with 21,329 genes represented. RESULTS: We identified 102 genes involved in various biologic processes that were differentially expressed between patient and control BMMCs; 53 of them are genes that are involved in major networks, including cell death, growth, signaling, and proliferation. Comparative analysis revealed 88 genes that were differentially expressed between bone marrow and blood, the majority of which are involved in cell growth and differentiation, cellular movement and morphology, immune response, and other hematopoietic cell functions. Unsupervised clustering of highly expressed genes revealed 2 major SLE patient clusters (active disease and inactive disease) based on gene expression in bone marrow, but not in peripheral blood. The up-regulated genes in the bone marrow of patients with active disease included genes involved in cell death and granulopoiesis. CONCLUSION: Microarray analysis of the bone marrow differentiated active from inactive SLE and provided further evidence of the role of apoptosis and granulocytes in the pathogenesis of the disease.
OBJECTIVE: The cells of the immune system originate from the bone marrow, where many of them also mature. This study was undertaken to examine gene expression in the bone marrow of patients with systemic lupus erythematosus (SLE), in order to better understand the aberrant immune response in this disease. METHODS: Bone marrow mononuclear cells (BMMCs) from 20 SLEpatients (11 with active disease and 9 with inactive disease) and peripheral blood mononuclear cells (PBMCs) from 27 patients (16 with active disease and 11 with inactive disease) were studied; BMMCs and PBMCs from 7 healthy individuals and 3 osteoarthritispatients were studied as controls. Samples were analyzed on genome-scale DNA microarrays, with 21,329 genes represented. RESULTS: We identified 102 genes involved in various biologic processes that were differentially expressed between patient and control BMMCs; 53 of them are genes that are involved in major networks, including cell death, growth, signaling, and proliferation. Comparative analysis revealed 88 genes that were differentially expressed between bone marrow and blood, the majority of which are involved in cell growth and differentiation, cellular movement and morphology, immune response, and other hematopoietic cell functions. Unsupervised clustering of highly expressed genes revealed 2 major SLEpatient clusters (active disease and inactive disease) based on gene expression in bone marrow, but not in peripheral blood. The up-regulated genes in the bone marrow of patients with active disease included genes involved in cell death and granulopoiesis. CONCLUSION: Microarray analysis of the bone marrow differentiated active from inactive SLE and provided further evidence of the role of apoptosis and granulocytes in the pathogenesis of the disease.
Authors: Alastair L Hepburn; Irvin A Lampert; Joseph J Boyle; Donna Horncastle; W Fai Ng; Mark Layton; Timothy J Vyse; Marina Botto; Justin C Mason Journal: Ann Rheum Dis Date: 2007-02-02 Impact factor: 19.103
Authors: Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens Journal: Proc Natl Acad Sci U S A Date: 2003-02-25 Impact factor: 11.205
Authors: Scott D Kobayashi; Kevin R Braughton; Adeline R Whitney; Jovanka M Voyich; Tom G Schwan; James M Musser; Frank R DeLeo Journal: Proc Natl Acad Sci U S A Date: 2003-09-05 Impact factor: 11.205
Authors: Lynda Bennett; A Karolina Palucka; Edsel Arce; Victoria Cantrell; Josef Borvak; Jacques Banchereau; Virginia Pascual Journal: J Exp Med Date: 2003-03-17 Impact factor: 14.307
Authors: William G Robichaux; Melissa Branham-O'Connor; Il-Young Hwang; Ali Vural; Johne H Kehrl; Joe B Blumer Journal: J Pharmacol Exp Ther Date: 2017-01-06 Impact factor: 4.030
Authors: Benjamin R Umiker; Shauna Andersson; Luis Fernandez; Parimal Korgaokar; Amma Larbi; Monika Pilichowska; Craig C Weinkauf; Henry H Wortis; John F Kearney; Thereza Imanishi-Kari Journal: Eur J Immunol Date: 2014-03-20 Impact factor: 5.532
Authors: Eneida Villanueva; Srilakshmi Yalavarthi; Celine C Berthier; Jeffrey B Hodgin; Ritika Khandpur; Andrew M Lin; Cory J Rubin; Wenpu Zhao; Stephen H Olsen; Matthew Klinker; David Shealy; Michael F Denny; Joel Plumas; Laurence Chaperot; Matthias Kretzler; Allen T Bruce; Mariana J Kaplan Journal: J Immunol Date: 2011-05-25 Impact factor: 5.422
Authors: Guillermo Barturen; Lorenzo Beretta; Ricard Cervera; Ronald Van Vollenhoven; Marta E Alarcón-Riquelme Journal: Nat Rev Rheumatol Date: 2018-01-24 Impact factor: 20.543
Authors: Justin H Fransen; Johan van der Vlag; Jurjen Ruben; Gosse J Adema; Jo H Berden; Luuk B Hilbrands Journal: Arthritis Res Ther Date: 2010-04-26 Impact factor: 5.156
Authors: Magdalene Nakou; George Bertsias; Ilias Stagakis; Michael Centola; Ioannis Tassiulas; Maria Hatziapostolou; Iraklis Kritikos; George Goulielmos; Dimitrios T Boumpas; Dimitrios Iliopoulos Journal: PLoS One Date: 2010-10-14 Impact factor: 3.240
Authors: Magda Nakou; Georgios Katsikas; Prodromos Sidiropoulos; George Bertsias; Eva Papadimitraki; Amalia Raptopoulou; Helen Koutala; Helen A Papadaki; Herakles Kritikos; Dimitrios T Boumpas Journal: Arthritis Res Ther Date: 2009-08-28 Impact factor: 5.156